Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Ameriprise Financial Inc.

Ameriprise Financial Inc. lowered its stake in shares of Acelyrin, Inc. (NASDAQ:SLRN) by 3.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 228,098 shares of the company’s stock after selling 8,564 shares during the quarter. Ameriprise Financial Inc. owned about 0.23% of Acelyrin worth $716,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. XTX Topco Ltd acquired a new stake in Acelyrin during the 4th quarter worth approximately $33,000. 4WEALTH Advisors Inc. purchased a new stake in shares of Acelyrin during the fourth quarter worth approximately $35,000. Hsbc Holdings PLC acquired a new stake in shares of Acelyrin during the fourth quarter worth $36,000. RPO LLC purchased a new position in Acelyrin in the 4th quarter valued at $46,000. Finally, Intech Investment Management LLC increased its stake in shares of Acelyrin by 71.0% during the fourth quarter. Intech Investment Management LLC now owns 26,587 shares of the company’s stock worth $83,000 after acquiring an additional 11,040 shares during the period. Institutional investors and hedge funds own 87.31% of the company’s stock.

Insider Activity

In related news, CEO Mina Kim sold 17,986 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $2.74, for a total value of $49,281.64. Following the sale, the chief executive officer now directly owns 671,753 shares in the company, valued at $1,840,603.22. The trade was a 2.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 13.60% of the company’s stock.

Acelyrin Price Performance

SLRN opened at $2.27 on Tuesday. Acelyrin, Inc. has a 12 month low of $1.85 and a 12 month high of $7.25. The stock has a market capitalization of $229.17 million, a P/E ratio of -0.92 and a beta of 1.07. The business has a 50 day simple moving average of $2.32 and a 200-day simple moving average of $2.69.

Acelyrin (NASDAQ:SLRN) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.95) by $0.40. Research analysts anticipate that Acelyrin, Inc. will post -2.53 EPS for the current year.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.